Profound Medical Q4 2024 Earnings Report

Profound Medical EPS Results

• Actual EPS: -$0.20
• Consensus EPS: -$0.31
• Beat/Miss: Beat by +$0.11
• One Year Ago EPS: N/A

Profound Medical Revenue Results

• Actual Revenue: $4.18 million
• Expected Revenue: $5.92 million
• Beat/Miss: Missed by -$1.74 million
• YoY Revenue Growth: N/A

Profound Medical Announcement Details

• Quarter: Q4 2024
• Date: 3/6/2025
• Time: After Market Closes
• Conference Call Date: Thursday, March 6, 2025
• Conference Call Time: 4:30PM ET

Profound Medical (NASDAQ:PROF), together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical Q4 2024 Earnings Call Transcript

Presentation

[Operator]

Thank you for standing by, and welcome to the Profound Medical Fourth Quarter and Full Year twenty twenty four Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question session. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Stephen Kimmel, Investor Relations.

[Operator]

Please go ahead, sir.

[Stephen Kilmer, Investor Relations at Profound Medical]

Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward looking statements within the meaning of applicable securities laws in The United States and Canada. All forward looking statements are based on Profound's current beliefs, assumptions and expectations and relate to, among other things, any expressed or implied statements or guidance regarding current or financial performance and position the expectations regarding the efficacy of ProFound's technology in the treatment of prostate cancer, BPH, uterine fibroids, palatal pain treatment and osteoid osteoma and its future revenues, financial results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.

[Stephen Kilmer, Investor Relations at Profound Medical]

No forward looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this conference call. Profound undertakes no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise, other than as required by law. Representing the company today are Doctor. Arun Benawat, Profound's Chief Executive Officer Reshed Dhawan, the company's Chief Financial Officer Doctor.

[Stephen Kilmer, Investor Relations at Profound Medical]

Matthew Burtnick, Profound's President and Tom Tamberrino, our Chief Commercial Officer. With that said, I'll now turn the call over to Richet.

[Rashed Dewan, CFO at Profound Medical]

Good afternoon, everyone, and welcome to our fourth quarter twenty twenty four conference call. On behalf of the management team and everyone at Profound, I would like to thank you for your ongoing interest in our company. For those of you who are shareholders, we appreciate your continued interest and support. I will turn the call over to Matthew in a moment to provide updates on Tulsa utilization trends and the CAPTAIN clinical trial. However, before I do, I would like to provide a brief summary of our fourth quarter twenty twenty four financial results.

[Rashed Dewan, CFO at Profound Medical]

To streamline things, all of the numbers I will refer to have been rounded, so they are approximate. For the three month period ended 12/31/2024, the company recorded revenue of $4,200,000 with $2,700,000 from recurring revenue and $1,500,000 from one time sale of capital equipment. Fourth quarter twenty twenty four revenue increased 108 from $2,000,000 from the same period in 2023. Gross margin in Q4 twenty twenty four was 71% compared to 52% in Q4 twenty twenty three. As previously stated, gross margin was very quarter to quarter due to product mix.

[Rashed Dewan, CFO at Profound Medical]

Total operating expenses in the twenty twenty four fourth quarter, which consists of R and D and SG and A expenses, were $11,300,000 compared with $9,800,000 in the fourth quarter of twenty twenty three. Overall, the company recorded a fourth quarter twenty twenty four net loss of $4,900,000 or $0.2 per common share, a 45% improvement compared to a net loss of $8,900,000 or $0.42 per common share for the same three month period in 2023. As of 12/31/2024, Profound had cash of $54,900,000 So to summarize, this was really our best quarter overall so far. We delivered record revenue of $4,200,000 record gross margin of 71 and lowest net loss since the first quarter of twenty twenty. We also ended the year with a strong balance sheet.

[Rashed Dewan, CFO at Profound Medical]

With that, I will now turn the call over to Matthew.

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

Thank you, Rishad. In the fourth quarter, there were 17 presentations featuring Telstra Pro at major society meetings, including the Interventional MRI Conference in Annapolis, Focal Plus in San Diego, the French Urology Congress in Paris, RSNA in Chicago and the Society of Urological Oncology in Dallas. These clinical presentations focus on the precision and flexibility of Tulsa as the only device that can safely deliver whole brand ablation for diffuse or multifocal prostate disease and targeted ablation for discrete disease. Precision is a keyword here because it is the MRI that gives physicians the precision they need to treat the types of patients they treat. MRI is the unparalleled precision to visualize the prostate.

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

MRI is the real time precision achieved by closed loop thermometry control. Meanwhile, precision is the 1.3 millimeter ablation accuracy proven on whole mouth histopathology from gold standard clinical treatment set studies. Precision is the ability to treat to the outer edge of the prostate without injury or leaving cancer behind. This precision is important because the nerve bundles that control erectile function run right along the side of the prostate all within two millimeters from the prostate surface. This precision is important because cancer grows right to the edges of the prostate.

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

Together with precision, the flexibility of the Tulsa technology, how it's designed to treat any region and any size prostate is what makes it uniquely positioned to become a mainstream treatment option for men with prostate disease. With all of the other ablative prostate technologies, those in the market, those recently cleared by the FDA or those that are coming down the pipeline, the fact of

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

the matter is that they

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

are all only well suited for single unifocal tumors and also only for very specific regions of the prostate. When we think about these devices, we can associate them with one of two categories. The first is one where they produce high temperature thermal tissue boiling and the second category is non thermal yet high pressure tissue destruction. With tissue boiling, there is so much energy being delivered in the tissue that it limits the actual volume of treatment achievable without starting to cause significant adverse effects. On the other hand, with high pressure tissue destruction, treating to the outer edge of the prostate, treating where cancer is typically located risks perforating the capsule, which then also causes significant adverse effects.

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

Tulsa is neither of these. Tulsa is controlled and gentle heating pixel by pixel, degree by degree. Tulsa is precision heating all the way to the outer edge of the prostate and even beyond, which is why we brought to market the Thermal Boost Tulsa AI module in response to requests from our physicians. When you compare apples to apples, whole gland to whole gland and focal to focal, Tulsa wins every time, again due to the precision of the technology and due to the flexibility of the ablation. To put some color to it, we know that HIFU and accoeblation can't get to the anterior of the prostate.

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

So right off the bat, that's thirty percent of cancer patients that don't qualify. It is also well accepted that only twenty five percent of patients have unifocal cancer suitable for focal therapy. Then considering the proportion of patients with disease right at the edge of the prostate, which we can conservatively estimate to be about fifty percent of the patients based on the real world usage of our Thermo Boost Tulsa ei module, we can easily see that in at least two thirds or more of the prostate cancer market, we are unique. If we evaluate on the following three axes: one, how much of the prostate volume you can ablate two, what kind of prostate disease patients you can treat and three, what range of prostate volumes you can treat, Tulsa is the only technology not just ablative, but of all prostate treatments that can effectively compete on these axes. This is based on the physics and science of Tulsa, which translates to an opportunity that is unique to us with an addressable market that is real and substantial, which ultimately speaks to the robust adaptability of the technology.

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

Finally, as I'm sure you're all wondering, we are delighted to remain on track with our CAPTAIN randomized trial comparing the Tulsa procedure to robotic radical prostatectomy. As of January 2025, '2 zero '1 patients were randomized and one hundred and seventy four patients were treated or scheduled for treatment. This represents the first randomized trial to have met its enrollment target comparing a new technology to a standard of care treatment for localized prostate cancer. We are honored and looking forward to the first impactful readout from Kapton at this year's AUA Annual Meeting in Las Vegas. I will now turn the call over to Tom to discuss where we stand with respect to planning and building our commercial organization to support growth.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Thank you, Matthew. It's a privilege to be here with all of you and thank you for your continued interest in our company. I had the privilege of reconnecting with Arun over the summer of twenty twenty four. It had been some time since we last talked following the acquisition of Novadec from Stryker and Arun had allowed me to take extensive time and due diligence while looking at the opportunity to join Profound. I had the chance to meet with Matthew, with Reshed, Board members and many others, including investors and Wall Street Analysts.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

The linchpin for me joining came when I attended the ProTalk Live event that took place in Las Vegas in September of twenty twenty four. And I had the privilege to hear our patient, Robert Palmer, who had gotten Tulsa Pro and was so pleased with the results that he's become an ambassador for the technology. After hearing his journey through prostate cancer and his treatment with Tulsa Pro and the reasons why he would only recommend it to other men facing prostate cancer, I messaged Arun at that very moment to let him know that it would be my privilege and honor to join Profound. I started in mid October and in one hundred and twenty days, I am proud to announce that we've done a complete turnaround of the commercial organization on a global scale. We have used no recruiters in our build out of the team and everyone is a known entity, whether that be from Novanac or Lifecell Corporation.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

The folks that we've been able to bring on the team are constant professionals and they are world class in sales and marketing and also in business development. As you heard from Rashed, we delivered in the fourth quarter and in the same breath in parallel, we've been able to transition from what was a placement model to a capital model, also as noted within our results from Q4. The individuals that joined us from EndoMag were a team of five. They took that organization's U. S.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Sales revenue from $8,000,000 to $32,000,000 in a five year period. That organization was recently acquired by Hologic. And the list goes on of other well known brand name entities within the medical device industry, whether that be Stryker, Intuitive Surgical, Imbuity, AxoGen, etcetera, we have a world class team. The organizational structure calls for a Vice President of Sales here in The United States, Adam Milligan. Reporting to Adam are two Directors of Sales.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Each Director of Sales has four Regional Business Directors and each Regional Business Director has three capital sales executives. In parallel, as business need requires, we will layer in clinical sales specialists who will focus on the adoption and drive volume procedures at the centers established by our capital sales executives. Our commercial strategy specific to The U. S. Is prototypical of anyone in the cancer arena, which of course we are, which is to focus on the top 50 cancer centers, many of which are already adopters of Tulsa Pro, added to which regional and bread and butter hospitals will also be in our target.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

We're agnostic to the diagnostics and we have the privilege to partner with Siemens, Philips, GE and other manufacturers in the MR space. We're also approaching a B2B market and we're looking to go with entities that have established portfolios of ambulatory surgical centers

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

as well as Log Posts.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

The beauty of being here at Profound is that when I compare it to my time at Novadek with ARUN, we had a sort of an empty chessboard in many ways. We didn't have as many chess pieces as we'd like when going to battle with the likes of a Stryker and Arthrex or Storz. But here at Profound, the chessboard is full. Everything is completely aligned. We have reimbursement as of January 1 through CMS.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

We have clinical data, as Matthew just mentioned, not only already in our repertoire, but forthcoming and we are developing a very robust and world class health economics and market access team. Our deliverables for 2025 are to create awareness of Tulsa Pro, to create access to Tulsa Pro, to drive adoption of Tulsa Pro and subsequently drive advocacy of Tulsa Pro at the physician level, at the patient level and at the private payer level. In terms of our revenue growth, if you look at what we accomplished in 2024, I believe is a great foundation to build on the future. I also believe that we will achieve similar or better to what we did in 2024, so something in the seventieth to seventy fifth ish percentage range in terms of growth. And once 2026 comes around barring any Black Swan events, we should be into the triple digital growth phase where we head up the shaft of the hockey stick.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Once again, thank you for your time. It's my privilege to turn the call over to Arun.

[Arun Menawat, Chairman & CEO at Profound Medical]

Thank you, Tom, and welcome to the company and good afternoon everyone. Overall, 2024 was a good year as we met or exceeded key operating goals, including revenue, margin, utilization per pulsar installed device, introduction of Tulsa AI modules, reimbursement and recruitment in the CAPTAIN trial. As you heard from Matthew, our clinical story is crystal clear. HealthSARS precision, flexibility and resulting TAM in prostate disease is unmatched by any competing technology. And HealthSaa's economic proposition is now clear as well.

[Arun Menawat, Chairman & CEO at Profound Medical]

Our urology APC level seven codes, which came into effect at the beginning of twenty twenty five, are not only paid at a higher level seven than our peers who are all at level six, but the codes are also applicable in an unrivaled range of treatment settings including hospitals and ASCs, imaging centers and office settings such as large urology practices. So a better procedure addressing a larger patient population reimbursed at a higher rate and also in more settings. To be frank, I think it's great to be in 2025 where we can now finally talk about top line growth. That's why I asked Tom to join us today and he will be on our calls going forward. As you heard from Tom today, he is already recruiting to add to our team of sales professionals and is also bolstering the sales management organization to prepare for the growth that we expect going forward.

[Arun Menawat, Chairman & CEO at Profound Medical]

We are also increasing our patient education programs to further build awareness of Telstra procedure among men and their caregivers. At the end of the day, it's all about patients and we already know from the feedback that we have received when provided with information about their options, prostate disease patients pick HealthSouth every time as their first treatment of choice. In the interest of time, I'm going to close out our prepared remarks here by summarizing the four key things we're looking forward to delivering this year. One, we expect that perioperative data from Kaptan to become available at AUA in April. We plan to use the results of this trial to help support additional acceptance or reimbursement by private insurance companies and seek addition of the Tulsa procedure as a treatment modality in Cancer Society guidelines.

[Arun Menawat, Chairman & CEO at Profound Medical]

Two, we are on track to introduce the BPH Tulsa AI module that will allow for customized treatment that is comparable in terms of speed to other modalities like Aqua Ablation. We plan to demo the BPH module at AUA in April. Our BPH application will focus first on those patients who need a surgical intervention instead of drug intervention. That segment of the market is approximately four hundred thousand patients per year tripling the total opportunity for Tulsa from about two hundred thousand cancer patients to a total of six hundred thousand prostate disease patients per year. Again, as a reminder, the TELSA AI BPH module will not require any hospital stay nor is there any post treatment meeting.

[Arun Menawat, Chairman & CEO at Profound Medical]

Three, another major initiative for ProFound this year is the introduction of Healthap Plus, which stands for selling both Healthapro and the Siemens interventional MRI, FreeMax as a combined total prostate solution. This solution streamlines the workflow and has the potential to be available in surgical suite of a hospital or an ASC or a urology clinic we plan to launch in the second half of twenty twenty five. And finally, we expect high double digit growth in 2025 with the proverbial hockey stick of rapid accelerated growth starting to form in late twenty twenty five, early '20 '20 '6 with triple digit revenue growth in 2026 and beyond. As we anticipate another dynamic year, we are laying plans to host a hybrid investor meeting at the AUA to showcase the Captain Perry operative results, the new ETH AI module and update investors further on the progress of the Tulsa Plus program. We'll provide the details as soon as they are available and hope you can join us either in person or virtually.

[Arun Menawat, Chairman & CEO at Profound Medical]

This ends our prepared remarks for today. With that, we're happy to take any questions you might have. Operator?

[Operator]

Certainly. And our first question comes from the line of Rick Wise from Stifel. Your question please.

[John McAulay, AVP at Stifel Financial Corp]

Hi, Arun and team. This is John on for Rick tonight. Maybe starting off on the commercial side of things, both Arun and Tom, you highlighted very strong double digit growth this year, 70, triple digit in the following years. Just I hope you can talk about what you've seen in the first few months of this post Medicare reimbursement environment that gives you the confidence to talk about such robust growth acceleration in the years ahead?

[Arun Menawat, Chairman & CEO at Profound Medical]

Sure, John. Good question. So I think that from the perspective of the clinical value of our product, as I've said before, we do not get much of a pushback. And that continues to be the case even more. From the perspective of the economics, we have put together pretty clear models that we can show to the hospitals that HealthSa can be a more profitable procedure for them with the higher reimbursement that we get.

[Arun Menawat, Chairman & CEO at Profound Medical]

And I think that even in Q4 in terms of what that means in terms of results, you can clearly see we had a pretty good quarter in terms of capital sales, because we did switch to that model. And in Q1, we have we've already sold capital sales. And so I guess that's about as much color I think I can give you the pipeline is pretty good. The sales team is energized. Tom, if you have any other comments, please feel free to mention it.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Absolutely. Thank you, Arun, John. Thanks for the question. I think you nailed it right on the head, Arun, specific to the clinical sale is one thing, the financial modeling sale is another, and then the last component is the adoption sale after the technology has been acquired. And my estimation from discussions with users who were very much cash pay only is that they have received many inquiries from folks now that there is coverage that they had not been hearing from before, which is a wonderful thing that we've created additional access for more men to be able to afford the Tulsa Pro procedure.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

And as was mentioned in the prepared remarks, we are taking a firm stance and going after the private payers to ensure the same in terms of covered lives with positive payer policies, so that even more men have an economical way to obtain access to Tulsa Pro. And in the same breath, it provides a healthy economic model for not only the facility, but also for the physician. So everybody wins. And I think those are the tailwinds that give us the confidence to make the statements we did specific to growth rates for this year and 2026 and beyond.

[John McAulay, AVP at Stifel Financial Corp]

Great. That's helpful. And just to build on something you mentioned in there, Tom. I just wanted to maybe get a better sense. Arun, in the past, had talked about reaching 75 sites by the end of twenty twenty five.

[John McAulay, AVP at Stifel Financial Corp]

And if you just had one, any update on that number and two, in terms of you guys talked about switching the model to capital sales. You were sort of doing a mix of capital and recurring in the past. Is it all capital now? Or is there still the recurring portion of the business in place as well?

[Arun Menawat, Chairman & CEO at Profound Medical]

So yes, let me answer the first part and I'll ask to cover the second part. In terms of the installed base, as we discussed in the Q3 call, we were not going to get to the 75 target last year. But as you can see from the recurring revenue, we did grow we grew nicely, but we did switch to the capital plus recurring model and that is where majority of our sales are at this point. And I think we will grow the installed base again in Q4. The only reason we decided not to give you the specific number today on what the installed base is or what resetting the target is because I do want to get a couple of quarters under our belt, particularly with this new model, so that we have some level of predictability.

[Arun Menawat, Chairman & CEO at Profound Medical]

But I think by second half of this year, we will start putting those numbers out for you as well. With respect to the deals, maybe you could address the

[Arun Menawat, Chairman & CEO at Profound Medical]

capital Absolutely.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Yes. Thank you, Arun. And John, thank you again for the question and happy to do so. I've got a few different comments in response to that inquiry. Number one is Profound Capital Solutions enables customers to obtain ownership of our technology through any number of means, right?

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Number one, of course, is this just a straight purchase order where it's direct from the person taking ownership, entity taking ownership and they're going to pay that invoice and pay in cash. As any other company would do, we offer solutions such as operating leases, capital leases, committed cost per procedure, agreements, etcetera to accelerate the adoption in lieu of capital budgeting cycles within your traditional hospital systems. So that's one comment I'll make there. And then I also want to make mention of the fact that the revenue streams that open up because of switching to the capital model is not only the capital infusion of course at the time of acquisition, not only the disposable revenue that comes from purchasing the kits that are required to complete each procedure, but of course the deferred revenue that will be building up over time specific to the service on those capital agreements in addition to the fact that we will continue to advance the AI capabilities and the software capabilities associated with the technology and that will be a fourth revenue stream that will provide further growth in the years to come.

[John McAulay, AVP at Stifel Financial Corp]

Got it. Thanks.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Thank you.

[Operator]

Thank you. Our next question comes from the line of Michael Freeman from Raymond James. Your question please.

[Michael Freeman, Equity Research Analyst - Healthcare at Raymond James Financial]

Thank you. Hey, good evening, Arun, Rashed, Matthew, Tom and Steve. Congrats on a strong finish to the year and thanks for these updates. One, my first question is around the, I guess, the launch and the demo of the BPH product. Nice to hear that you're going to sort of reveal this thing at AUA.

[Michael Freeman, Equity Research Analyst - Healthcare at Raymond James Financial]

Wondering if one, is there updated timing on the launch of that product? And are there any associated regulatory clearances for that module that need clearing before you can launch?

[Arun Menawat, Chairman & CEO at Profound Medical]

Sure. Matthew, do you want to take that question?

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

Sure. Yes. Thank you, Michael, for the question. We are delighted to be in a position to be able to demo the BPH modules with a timeframe of AUA. I think we've been talking about a midyear timeline for a launch of the product.

[Mathieu Burtnyk, Chief Operating Officer at Profound Medical]

So it certainly falls in line with that. And again, these are a set of modules that incorporate AI as well as non AI in order to streamline the procedure for total skin to skin time within an average of about sixty to ninety minutes. So we do think that we're on track for that. From a regulatory standpoint, I don't know if I can comment specifically on that, but we have that as part of our project plan for the launch mid year as discussed.

[Michael Freeman, Equity Research Analyst - Healthcare at Raymond James Financial]

Okay. All right, great. Thank you very much for that. I have another question here. I wonder, now that you're much of the way through your first quarter, you mentioned that you have had some more placements.

[Michael Freeman, Equity Research Analyst - Healthcare at Raymond James Financial]

I wonder if you could just talk about utilization and talk about uptake among Medicare payers. You mentioned that there was an uptick in inquiries that you're hearing from your from the doctors in your network. I wonder if you have seen an uptick in actual payments through Medicare in your first quarter?

[Arun Menawat, Chairman & CEO at Profound Medical]

Oh, no, the actual payments? Like a payments typically take Medicare takes a long time to pay. So I don't have good data on the actual payment. I don't see any issue with it at all, but I don't think we have a lot of data on the payments itself. I think based upon the Q4 recurring revenue, you'll see the numbers are certainly are up.

[Arun Menawat, Chairman & CEO at Profound Medical]

And I think the trend is, as Tom described are up as well. We are getting sporadic, very early stage data also that in certain centers, some of the bigger private insurance companies are paying. And in some cases, they're paying after pre authorization. In some cases, they have they do provide a number to the patient before the after the procedure and they are paying. And from what we hear, the sites are happy with what they're getting.

[Arun Menawat, Chairman & CEO at Profound Medical]

We obviously don't know what the exact numbers are, but I don't I think we generally are hearing satisfied users from that perspective.

[Michael Freeman, Equity Research Analyst - Healthcare at Raymond James Financial]

Okay. That's great. And just a quick follow-up to that. With those some of the larger private insurance companies providing payments either with or without pre auth, Are these I mean, these seem like obvious targets for first conversations even without the capsid data. Do you have, I guess, reimbursement personnel pursuing these specific companies as first targets?

[Arun Menawat, Chairman & CEO at Profound Medical]

Yes. So Michael, I've talked about this before that given that ablative therapies are becoming more prevalent and insurance companies have been paying. I think that our job in terms of getting payments is not as insurmountable as if we were the first ablative therapy out there. So, I do think that this is work in progress, it's going to happen. Captan trial results will definitely help significantly.

[Arun Menawat, Chairman & CEO at Profound Medical]

But to answer your direct question, we are in Tom's team, we are adding a team that is going to explicitly develop a strategy of which insurance companies to go after first and prioritize them. And ultimately, we will get there to all the major players. How we make that priority decision will be right in the sense that some of it will be based upon which companies are already paying and how many centers, what has been the dialogue. It will also depend on certain regions where we have a bigger install base, so it will have an impact. So there are a number of different things that we will look at and which companies we go after first.

[Arun Menawat, Chairman & CEO at Profound Medical]

But I think in general, the theme of what you're discussing is right on our strategy that we have specialized people who are going to be working on this and we don't expect major issues. The timing is going to be whatever standard timings are for these things, but we don't expect that to be major issues.

[Tom Tamberrino, Chief Commercial Officer at Profound Medical]

Okay.

[Michael Freeman, Equity Research Analyst - Healthcare at Raymond James Financial]

Thank you very much. I'll pass it on now.

[Operator]

Thank you. And this does conclude the question and answer session of today's program. I'd like to hand the program back to Doctor. Benoit for any further remarks.

[Arun Menawat, Chairman & CEO at Profound Medical]

Thank you so much. And we are looking forward to not just Q1, but also hopefully everyone joining us as we provide more details for the virtual or hybrid conference that we will have at the AUA in April this year. Thank you.

[Operator]

Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.

[Rashed Dewan, CFO at Profound Medical]

Thank you.

Participants

Executives

• Stephen Kilmer, Investor Relations
• Rashed Dewan, CFO
• Mathieu Burtnyk, Chief Operating Officer
• Tom Tamberrino, Chief Commercial Officer
• Arun Menawat, Chairman & CEO

Analysts

• John McAulay, AVP at Stifel Financial Corp
• Michael Freeman, Equity Research Analyst - Healthcare at Raymond James Financial